Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?

Slides:

Advertisements

Similar presentations

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.

Advertisements

Glycemic Control: When the Lower is Not the “Better”?

Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.

Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals

LEADER trial: Primary Outcome

Cardiovascular Outcomes Trials in Diabetes: The Truth, the Whole Truth, and Nothing But the Truth.

Pravastatin in Elderly Individuals at Risk of Vascular Disease

AIM HIGH Niacin plus Statin to prevent vascular events

The Latest Lipid Guidelines:

Updates and Perspectives in Diabetic Dyslipidemia

What is the likely mechanism by which HDL-C reduces coronary heart disease?

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

The PPAR Journey: What Can We Expect in the Future?

The PPAR Journey: What Can We Expect in the Future?

Panelists. Type 2 Diabetes, Renal Impairment, and CHD: Reducing 2 Vascular Risks With 1 Stone.

An Endocrinology Clinic in Dyslipidemia

Omega-3 Prescriptions vs Supplements in Practice

New Insights on PPAR Agonists For Cardiovascular Disease

Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective

Cardiovascular Disease Risk Reduction Advances in Dyslipidemia

Cholesteryl Ester Transfer Protein Inhibitors

Obesity and Dyslipidemia: How Would You Treat?

Shedding Light on HDL: Myths and Controversies

Early Type 2 Diabetes Mellitus: A Cardiovascular Disease

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population

Impacting CV Risk With Diabetes Medications

LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

Impacting CV Risk With Diabetes Medications

TNT Study: Baseline Characteristics of the Patients

Panelists. Secondary Prevention of Macrovascular Events in Type 2 Diabetes: Focus on Dyslipidemia.

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

Diabetes Increases Risk of CVD

An Update on PCSK9 Inhibitors

Evaluating LDL-C Recommendations

What's New in Dyslipidemia?

Statins and Glucose Metabolism: Are All Agents Alike?

Growing Diabetes Pandemic Worldwide

A Journal Club on Lipid Management:

UKPDS 35: Impact of Increasing A1c on Cardiovascular Disease in T2DM

PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?

Cardiometabolic Risk: What Can the PPAR-Alpha Agonists Teach Us?

Diabetes and Cardiovascular Disease Risk: The Hard Truth

Learning Objectives Metabolic Abnormalities Associated With T2D.

Lipid Clinic Challenge

The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.

Diabetes and Cardiovascular Disease Risk: The Hard Truth

Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population

Updates in Cardiovascular Medicine

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Residual CV Risk in Patients With Dyslipidemia and Stable CAD

Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?

T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

Pharmacotherapy for Diabetic Coronary Disease:

Statins, Obesity, and Hyperlipidemia

LDL Cholesterol.

How to Optimize Cholesterol Management in High-Risk CV Patients

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Elevated Admission Plasma Glucose Following ACS

Potential mechanisms whereby statins may reduce the risk of stroke

DECLARE-TIMI 58.

New Lipid-Lowering Guidelines

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

An Update on PCSK9 Inhibitors

Characteristics of included studies

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Presentation transcript:

Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?

Panelists

Learning Objectives

Learning Objectives

Diabetes as a CV Risk Factor

Impact of Gluco-Metabolic Characteristics on Risk of Major Cardiovascular Events

Risk Factors in Patients With T2D After ACS

The HDL Hypothesis

Meta-analysis of Intensive Statin Trials: Coronary Death or Myocardial Infarction

Intensive Glucose Control in Critically Ill Patients: Death From Any Cause

UKPDS: Extended Follow-up Benefits of Glycemic Control

Comparison of CETP Inhibitors

DAL-OUTCOMES: 3 Years

AIM-HIGH: End Point at 36-month Follow-up

ACCORD Lipid: Hazard Ratios for the Primary Outcome

SYNCHRONY: Effect of Aleglitazar on Cardiometabolic Parameters in T2D

AleCardio: Aleglitazar in Patients With T2D and ACS

Unmet Needs: Diabetes in Post-ACS Patients

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)